Regulatory Submission Blog

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

The DART pilot is getting ready to fly

Marc Ellison

The FDA’s SENDIG-DART pilot is finally here! This new SEND standard covers Embryo-Fetal Development studies with 7 new domains, building on SEND 3.1. It’s been a long journey from development to this pilot – exciting...

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

There is nothing permanent except change

Marc Ellison

SEND keeps changing fast. Recently, FDA made it clear that SEND requirements go beyond just studies placed in the eCTD, if a study can be represented in SEND, it should be. This broadens the scope...

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

SEND: Why did they have to make it so damn hard?!

Marc Ellison

At first, I thought SEND would be simple, just standardizing study data like any other. But it’s far more complex, involving multiple overlapping standards, evolving regulations, and even clinical concepts awkwardly adapted for nonclinical use....

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

A SEND nerd

Marc Ellison

Hi, I’m Marc, a SEND nerd for over 8 years. My first SEND meeting was like learning a new language, but I quickly got hooked. Now I blog about the challenges and future possibilities of...

Stay up to Date

Get expert tips, industry news, and fresh content delivered to your inbox.